靶向整合素αvβ3与CD13的白蛋白结合剂偶联异二聚体放射性药物的开发与评价及其在肿瘤治疗中的应用
本研究基于HX01结构合成新型白蛋白结合剂偶联化合物,经68Ga标记后在BxPC-3异种移植小鼠模型中进行小动物PET/CT显像与体内外评价。其中[68Ga]Ga-L6较无白蛋白结合剂的[68Ga]Ga-L0及既往白蛋白结合剂化合物[68Ga]Ga-L7表现出显著增强的肿瘤摄取与滞留。经177Lu标记的[177Lu]Lu-L6在SPECT/CT与离体生物分布中显示正常组织快速清除、高肿瘤摄取与延长滞留,作者认为其是放射治疗的理想候选化合物。
要点
- 基于HX01结构合成白蛋白结合剂偶联化合物,68Ga标记后均显示改善的药代动力学。
- [68Ga]Ga-L6较[68Ga]Ga-L0显著增强肿瘤摄取与滞留,并优于[68Ga]Ga-L7。
- [177Lu]Lu-L6正常组织快速清除、肿瘤摄取高且滞留延长,作者认为适合放射治疗。
核心结论
- 筛选出靶向整合素αvβ3与CD13的新化合物,含新型白蛋白结合剂,在BxPC-3肿瘤中肿瘤摄取增加、滞留延长,正常器官背景低。
- 作者认为该化合物经177Lu标记后是放射治疗的理想候选化合物。
研究设计与样本
- 基于HX01结构合成新型白蛋白结合剂偶联化合物,68Ga标记后进行体外与体内评价。
- 使用BxPC-3异种移植小鼠模型,于注射后0.5-6小时不同时间点行小动物PET/CT显像。
- 成像表现最佳的化合物进一步用177Lu标记,行小动物SPECT/CT与离体生物分布研究。
主要发现
- 所有新型白蛋白结合剂偶联化合物经68Ga标记后均显示改善的药代动力学。
- 小动物PET/CT显示新型白蛋白结合剂偶联化合物(尤其[68Ga]Ga-L6)较无白蛋白结合剂的[68Ga]Ga-L0显著增强肿瘤积聚与滞留。
- [68Ga]Ga-L6优于采用既往报道白蛋白结合剂开发的[68Ga]Ga-L7。
- [177Lu]Lu-L6在小动物SPECT/CT与生物分布研究中显示正常组织快速清除、高肿瘤摄取与延长滞留。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: The advancement of heterodimeric tracers, renowned for their high sensitivity, marks a significant trend in the development of radiotracers for cancer diagnosis. Our prior work on [68Ga]Ga-HX01, a heterodimeric tracer targeting CD13 and integrin αvβ3, led to its approval for phase I clinical trials by the China National Medical Production Administration (NMPA). However, its fast clearance and limited tumor retention pose challenges for broader clinical application in cancer treatment. This study aims to develop a new radiopharmaceutical with increased tumor uptake and prolonged retention, rendering it a potential therapeutic candidate. METHODS: New albumin binder-conjugated compounds were synthesized based on the structure of HX01. In vitro and in vivo evaluation of these new compounds were performed after labelling with 68Ga. Small-animal PET/CT imaging were conducted at different time points at 0.5-6 h post injection (p.i.) using BxPC-3 xenograft mice models. The one with the best imaging performance was further radiolabeled with 177Lu for small-animal SPECT/CT and ex vivo biodistribution investigation. RESULTS: We have synthesized novel albumin binder-conjugated compounds, building upon the structure of HX01. When radiolabeled with 68Ga, all compounds demonstrated improved pharmacokinetics (PK). Small-animal PET/CT studies revealed that these new albumin binder-conjugated compounds, particularly [68Ga]Ga-L6, exhibited significantly enhanced tumor accumulation and retention compared with [68Ga]Ga-L0 without an albumin binder. [68Ga]Ga-L6 outperformed [68Ga]Ga-L7, a compound developed using a previously reported albumin binder. Furthermore, [177Lu]Lu-L6 demonstrated rapid clearance from normal tissues, high tumor uptake, and prolonged retention in small-animal SPECT/CT and biodistribution studies, positioning it as an ideal candidate for radiotherapeutic applications. CONCLUSION: A new integrin αvβ3 and CD13 targeting compound was screened out. This compound bears a novel albumin binder and exhibits increased tumor uptake and prolonged tumor retention in BxPC-3 tumors and low background in normal organs, making it a perfect candidate for radiotherapy when radiolabeled with 177Lu.
引用
- Yang B, Shan C, Song X, et al. Development and evaluation of albumin binder-conjugated heterodimeric radiopharmaceuticals targeting integrin αvβ3 and CD13 for cancer therapy. Eur J Nucl Med Mol Imaging. 2024. PMID: 38787395. doi:10.1007/s00259-024-06766-y
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。